Intricon Hires David Liebl as Vice President of R&D
09 Agosto 2021 - 9:00AM
Intricon Corporation (NASDAQ: IIN)
, an
international company engaged in designing, developing,
engineering, and manufacturing miniature interventional,
implantable and body-worn medical devices, today announced that
David Liebl has joined the company as Vice President of R&D,
effective today.
“We are very excited to welcome Dave to the Intricon team. His
rich and diverse background combining technology, business and
product development, regulatory affairs and M&A made him an
ideal fit for this new key leadership position,” said Scott
Longval, President and Chief Executive Officer of Intricon. “Over
the past 18 months, one of our priorities has been to expand and
strengthen our talent to enhance our position as a Joint
Development Manufacturer and the addition of Dave further
highlights our progress.”
Mr. Liebl’s career includes more than 25 years of engineering
and product development experience at multiple high technology and
medical technology companies. Most recently he served as the
President of Biomerics NLE’s West Operations. Prior to his role at
Biomerics, he held several roles at Heraeus Medical
Components/NeoMetrics, Inc., including EVP, Product and Business
Development, President and CTO, and VP, Development spanning from
2005 to 2019. His career also includes Director and Vice President
level positions at Pearson, Datacard Group, and MedAmicus, Inc.
(now part of Integer Holdings).
“I am thrilled by the opportunity to join Intricon,” said Mr.
Liebl. “I am confident that my broad background will enable me to
drive significant value as we continue to explore opportunities in
high growth markets and enhancements to our technology.”
About Intricon CorporationIntricon is
a Joint Development Manufacturer that integrates components and
assemblies to advance micro-medical technology across a range of
device platforms for global
customers. Intricon approaches each engagement with an
all-in commitment, working with customers every step of the
way—from the earliest idea stages to ongoing production—in order to
advance program performance and deliver results. With a focus on
key device platforms, Intricon helps advance clinical
outcomes by always looking ahead with proactive support and
resources through integration of its core
competencies. Intricon has facilities in the United
States, Asia and Europe. The company's common stock
trades under the symbol "IIN" on the NASDAQ Global Market.
Investor Relations Contact:Leigh Salvo(415)
937-5404investorrelations@intricon.com
Intricon (NASDAQ:IIN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Intricon (NASDAQ:IIN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024